Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1908843
22 May 2024 01:43PM

Shareholders approve dividend doubling to EUR 1.00


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): AGM/EGM
CompuGroup Medical Annual General Meeting: Shareholders approve dividend doubling to EUR 1.00

22.05.2024 / 13:43 CET/CEST
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical Annual General Meeting: Shareholders approve dividend doubling to EUR 1.00

  • Acts of the governing boards formally approved
  • Dividend proposal of EUR 1.00 confirmed
  • High approval rates for capital measures
  • Focus on data-based solutions and artificial intelligence

 

Koblenz - The shareholders of CompuGroup Medical SE & Co. KGaA (CGM) approved the dividend proposal of the General Partner, the Supervisory Board and the Managing Directors at the e-health group's virtual Annual General Meeting (AGM) on May 22, 2024. As a result, a dividend of EUR 1.00 per share will be paid for the financial year 2023, twice as much as in the previous year. This corresponds to a payout of around EUR 51.7 million. The shareholders also approved all proposed capital measures by majorities of more than 90 percent such as the enactment of authorized capital, the authorization to issue convertible bonds and share options or the authorization to acquire and use treasury shares.

The shareholders approved the annual financial statements of CompuGroup Medical SE & Co. KGaA for 2023 and passed the remuneration report for 2023. The actions of the General Partner of CompuGroup Medical SE & Co. KGaA and the members of the Supervisory Board were formally approved.

All other items on the agenda were also approved by the shareholders with a large majority. A total of around 79 percent of the share capital of CompuGroup Medical SE & Co. KGaA was represented at the Annual General Meeting. The speeches by CEO Michael Rauch and CFO Daniela Hommel, who has been in office since February 1, were published beforehand online. A video replay of both speeches will be made avaailable subsequently on the company's website.

In his speech, CGM CEO Michael Rauch addressed the 2023 financial year and the future development of the company. He said: “The medicine of the future will be digital, data-based and interconnected. That is why we are focusing on data-based solutions, Artificial Intelligence, the analysis of medical data and real-time access. CompuGroup Medical is well prepared for this future.” 

CFO Daniela Hommel introduced herself to CGM’s shareholders during her first AGM speech. With respect to the financials, she emphasized that CompuGroup Medical is growing organically at a sustainably high level: “The increase in revenues and earnings in 2023 contributed to a high free cash flow of EUR 113 million. We have a strong business model. The results confirm the path that we want to keep pursuing: sustainable profitable growth.”

The complete documents relating to the Annual General Meeting can be found on our website: Annual General Meeting - Investor Relations - Company - cgm.com.



22.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1908843

 
End of News EQS News Service

1908843  22.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1908843&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.